Ovid Therapeutics Overview
Share Price
$5.73
(As of Wednesday Closing)
Ovid Therapeutics General Information
Description
Ovid Therapeutics Inc is a US based biopharmaceutical company. The firm is engaged primarily in developing impactful medicines for patients and families living who are suffering with rare neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.
Want to dig into this profile?
We’ll help you find what you need
Learn more
Ovid Therapeutics Stock Performance
(As of Tuesday closing)
| Stock Price |
Previous Close |
52 wk Range |
Market Cap |
Shares |
Average Volume |
EPS |
| $5.73 |
$6.69 |
$1.53 - $7.21 |
$366M |
54.8M |
778K |
-$1.49 |
Ovid Therapeutics Financials Summary
In Thousands,
USD
|
TTM
31-Mar-2020
|
FY 2019
31-Dec-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
| EV |
86,298 |
160,530 |
7,155 |
146,792 |
| Revenue |
0 |
0 |
0 |
0 |
| EBITDA |
(67,405) |
(61,155) |
(52,790) |
(64,927) |
| Net Income |
(66,691) |
(60,461) |
(51,980) |
(64,806) |
| Total Assets |
61,723 |
80,844 |
47,650 |
89,458 |
| Total Debt |
0 |
0 |
0 |
0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ovid Therapeutics Valuation & Funding
| Deal Type |
Date |
Amount |
Valuation/
EBITDA |
Post-Val |
Status |
Debt |
This information is available in the PitchBook Platform. To explore Ovid Therapeutics‘s full profile, request access.
Request a free trial
Ovid Therapeutics Cap Table
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion
Price |
% Owned |
This information is available in the PitchBook Platform. To explore Ovid Therapeutics‘s full profile, request access.
Request a free trial
Ovid Therapeutics Competitors (9)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| Auspex Pharmaceuticals |
Formerly VC-backed |
San Diego, CA |
00 |
00000 |
000000&0 |
00000 |
| 0000000000 |
Formerly PE-Backed |
Germantown, MD |
0 |
000.00 |
00000000 |
000.00 |
| 00000000 000000000 |
Formerly VC-backed |
Coral Gables, FL |
00 |
000.00 |
00000000 |
000.00 |
| 000000000 |
Venture Capital-Backed |
New York, NY |
|
000.00 |
00000000000 |
000.00 |
| 0000000 |
Venture Capital-Backed |
San Mateo, CA |
00 |
000.00 |
00000 00000 |
000.00 |
Ovid Therapeutics Executive Team (14)
| Name |
Title |
Board Seat |
Contact Info |
| Jeremy Levin Ph.D |
Chief Executive Officer & Chairman |
|
|
| Amit Rakhit MD |
Chief Medical Officer & President |
|
|
| Timothy Daly |
Chief Financial Officer, Finance & Chief Accounting Officer, Accounting |
|
|
| Dirk Haasner Ph.D |
Senior Vice President |
|
|
| Suzanne Wakamoto |
Senior Vice President, Human Resources |
|
|
6 Former Executives
Ovid Therapeutics Board Members (6)
To view Ovid Therapeutics‘s full board member team, request access >>
| Name |
Representing |
Role |
Since |
| Bart Friedman JD |
Self |
Board Member |
000 0000
|
| Douglas Williams Ph.D |
Self |
Board Member |
000 0000
|
| Howard Federoff Ph.D |
Self |
Chairman, Scientific Advisory Board |
000 0000
|
| Jeremy Levin Ph.D |
Ovid Therapeutics |
Chief Executive Officer & Chairman |
000 0000
|
| Karen Bernstein Ph.D |
Self |
Board Member |
000 0000
|
1 Former Board Member